FTSE MIB
33.565,30 -388,98 (-1,15%) Dow Jones
37.735,11 -248,13 (-0,65%) Nasdaq
15.885,02 -290,08 (-1,79%) Nikkei 225
38.471,20 -761,60 (-1,94%) Petrolio
84,98 -0,43 (-0,50%) Bitcoin EUR
59.261,02 -2.987,02 (-4,80%)
Enzo Biochem, Inc. (0IHV.L)
| Chiusura precedente | 1,2310 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 1.019 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 0,71 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,1400 |
| Prossima data utili | 12 giu 2024 - 17 giu 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireEnzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO
FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo’s Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. “We thank Hamid for the commitment he has brought to Enzo Biochem, Inc.” Chairperson of the Board Mary Tagliaferri, MD stated, “Hamid successfully led the Co
- GlobeNewswire
Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp
Significant value unlocked for Enzo shareholders with continued focus on life sciences. FARMINGDALE, NY, July 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has closed a transaction to sell certain assets of Enzo’s Clinical laboratory division (Enzo Clinical Labs) to Laboratory Corporation of America Holdings (Labcorp) (NYSE:LH) pursuant to an Asset Purchase Agreement dated March 16, 2023, as amended July 3, 2023. ASSET SALE Enzo Biochem has completed the prev
- GlobeNewswire
Enzo Biochem Reports Third Quarter Fiscal Year 2023 Financial Results
- Enzo Life Sciences reports revenue of $7.5 million, with margin improvement in Q3 FY23 FARMINGDALE, NY, June 14, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, today filed its Form 10-Q for the third quarter ended April 30, 2023 of Fiscal Year 2023 (Q3 FY23). Enzo Biochem will not be hosting a financial webcast or call for this most recent quarterly reporting period. As previously reported, on March 16, 2023, Enzo Biochem announced tha
